- $26.71bn
- $27.55bn
- $4.34bn
Brief: Illumina To Announce First Quarter 2026 Financial Results On Thursday, April 30, 2026
Brief: Illumina And Labcorp Expand Collaboration To Broaden Access To Precision Oncology Testing
Grail CEO Bob Ragusa to retire, Josh Ofman named successor
Brief: Illumina Partners Go Beyond The Genome, Driving Cancer Breakthroughs
Illumina beats Q4 adjusted EPS estimates
Brief: Illumina Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology
Illumina rises after forecasting Q4 results beat
Brief: Illumina Introduces Billion Cell Atlas To Accelerate Ai And Drug Discovery
Illumina unveils dataset to speed up AI-powered drug discovery
Brief: Illumina Introduces Billion Cell Atlas, Genome-Wide Genetic Perturbation Dataset
Illumina Q4 preliminary revenue rises 5%, beats analyst expectations
Life sciences and contract research stocks navigate turbulence in 2025
Jefferies updates ratings on life sciences firms for 2026
Brief: Illumina Inc Files For Offering Of $500 Million 4.750% Notes Due 2030
Timeline: Trump's trade war with China in 2025
U.S. RESEARCH ROUNDUP-Doordash, Honeywell, Zscaler
Timeline: Trump's trade war with China in 2025
Brief: Illumina Responds To Positive Updates From Chinese Ministry Of Commerce
U.S. STOCKS ON THE MOVE-Targa Resources, Illumina, Alphabet